Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

Launched by M.D. ANDERSON CANCER CENTER · Aug 9, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the early signs of oral cancer and how it progresses. Researchers want to collect tissue samples and other biological materials from patients with oral premalignant (early warning signs) or malignant (cancerous) tumors. By studying these samples before, during, and after treatment, the goal is to discover new ways to predict how well patients will respond to different treatments like surgery, chemotherapy, or immunotherapy. This information could help doctors make better decisions about the best treatment options for future patients.

To be eligible for the trial, participants must be 18 years or older and have been diagnosed with certain oral conditions, such as leukoplakia (white patches in the mouth) or squamous cell carcinoma (a type of oral cancer). Patients must also be able to give informed consent and have their tumors evaluated at the MD Anderson Cancer Center for the first time or have a recurrence of previously treated tumors. It’s important to note that pregnant women and individuals with cognitive impairments cannot participate in this study. If you join the trial, you can expect to provide samples and receive close monitoring of your treatment response, contributing to valuable research that may help others in the future.

Gender

ALL

Eligibility criteria

• • Aged 18 or older, with a diagnosis of oral premalignant or malignant tumors (eligible diagnoses listed below) or presenting with suspected premalignant or malignant tumors for definitive diagnosis
• • Must be able to provide informed consent
• • Oral premalignant or malignant tumors presenting for evaluation for the first time at UT MD Anderson Cancer Center
• • Oral premalignant or malignant tumors who were previously treated or evaluated at UT MD Anderson Cancer Center who presents for evaluation of progressive or recurrent disease. Newly collected biospecimens and tissue samples will be linked to applicable samples previously collected and banked/stored under PA17-0050, LAB02-427, Lab02-039 and Lab08-0848.
• Eligible diagnoses include:
• • Leukoplakia
• • Erythroplakia
• • Mild dysplasia
• • Moderate dysplasia
• • Severe dysplasia
• • Carcinoma in situ
• • Squamous cell carcinoma
• Exclusion:
• • - Pregnant women and/or cognitively-impaired adults are excluded from this study.
• Exclusion Criteria:
• • - Prior oral squamous cell carcinoma (OSCC) surgery or OSCC radiation treatment at a non-MDA institution.